Download PDF
Klin Monbl Augenheilkd 2015; 232(6): 754-764
DOI: 10.1055/s-0035-1546032
Übersicht
Georg Thieme Verlag KG Stuttgart · New York

Keratomykose – Therapiestandards und aktuelle Entwicklungen

Keratomycosis – Therapy Standards and New Developments
W. Behrens-Baumann
1   Universitätsaugenklinik, Otto-von-Guericke-Universität Magdeburg
,
D. Finis
2   Augenklinik, Heinrich-Heine-Universität Düsseldorf
,
C. MacKenzie
3   Institut für Medizinische Mikrobiologie und Krankenhaushygiene, Heinrich-Heine-Universität Düsseldorf
,
M. Roth  
2   Augenklinik, Heinrich-Heine-Universität Düsseldorf
,
G. Geerling  
2   Augenklinik, Heinrich-Heine-Universität Düsseldorf
› Author Affiliations
Further Information

Publication History

eingereicht 03 March 2015

akzeptiert 17 April 2015

Publication Date:
17 June 2015 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Die mykotische Keratitis ist ein verhältnismäßig seltenes, aber sehr ernst zu nehmendes ophthalmologisches Krankheitsbild mit potenziell visusbedrohendem Verlauf. Seit etwa 2 Jahrzehnten ist eine Häufigkeitszunahme der Pilzkeratitis festzustellen, möglicherweise bedingt durch die vermehrte Verwendung von weichen Kontaktlinsen. Dieser Beitrag gibt einen Überblick über die typischen klinischen Zeichen und Symptome der Keratomykose und stellt Bewährtes sowie neue Entwicklungen und Erkenntnisse im Bereich der Diagnostik und Therapie der mykotischen Keratitis dar.

Abstract

Mycotic keratitis is a comparatively rare but serious ophthalmological disease, that can possibly lead to a severe loss of vision up to blindness. Over the last two decades an increase of cases with mycotic keratitis has been noticed, which is possibly caused by an increased use of soft contact lenses. This article gives an overview of the typical clinical signs and symptoms of keratomycosis, tried and tested diagnostics and therapy as well as new diagnostic and therapeutic developments and findings.

Schlüsselwörter

Mikrobiologie - Infektiologie - Kornea

Key words

microbiology - infectious diseases - cornea

Diese Autoren sind gemeinsam korrespondierende Autoren.


 

  • Literatur

  • 1 Leber T. Keratomycosis aspergillina als Ursache von Hypopyonkeratitis. Graefe Arch Ophthal 1879; 25: 285-301
    PubMedGoogle Scholar
  • 2 Schirmer O. Ein Fall von Schimmelpilzkeratitis. Graefe Arch Ophthal 1896; 42: 131-139
    PubMedGoogle Scholar
  • 3 Uhthoff W. Beiträge zur pathologischen Anatomie des Auges. Graefe Arch Ophthal 1883; 29: 178-181
    PubMedGoogle Scholar
  • 4 Uhthoff W, Axenfeld T. Beiträge zur pathologischen Anatomie und Bakteriologie der eitrigen Keratitis des Menschen. Graefe Arch Ophthal 1896; 42: 114-127
    PubMedGoogle Scholar
  • 5 Hoffmann DH, Schmitz R. Die experimentelle Keratomykose als Beitrag zur Frage des Cortisonschadens am Auge. Ein vorläufiger Bericht. Mykosen 1963; 6: 12-20
    PubMedGoogle Scholar
  • 6 Neuhann T, Blassmann K, Roth HW. Pilzwachstum auf weichen Kontaktlinsen. Klin Monatsbl Augenheilkd 1978; 173: 648-653
    PubMedGoogle Scholar
  • 7 Yamamoto GK, Pavan-Langston D et al. Stowe GC 3rd et al. Fungal invasion of a therapeutic soft contact lens and cornea. Ann Ophthalmol 1979; 11: 1731-1735
    PubMedGoogle Scholar
  • 8 Fleiszig SM, Evans DJ. Pathogenesis of contact lens-associated microbial keratitis. Optom Vis Sci 2010; 87: 225-232
    PubMedGoogle Scholar
  • 9 Butler TK, Males JJ, Robinson LP et al. Six-year review of Acanthamoeba keratitis in New South Wales, Australia: 1997–2002. Clin Experiment Ophthalmol 2005; 33: 41-46
    CrossrefPubMedGoogle Scholar
  • 10 Imamura Y, Chandra J, Mukherjee PK et al. Fusarium and Candida albicans biofilms on soft contact lenses: model development, influence of lens type, and susceptibility to lens care solutions. Antimicrob Agents Chemother 2008; 52: 171-182
    CrossrefPubMedGoogle Scholar
  • 11 Behrens-Baumann W. Mycosis of the Eye and its Adnexa. Basel: Karger Medical and Scientific Publishers; 1999: 68-107
    CrossrefGoogle Scholar
  • 12 Behrens-Baumann W. Diagnostik und Therapie der Keratomykose. Ophthalmologe 2009; 106: 471-481
    CrossrefPubMedGoogle Scholar
  • 13 Nielsen SE, Nielsen E, Julian HO et al. Incidence and clinical characteristics of fungal keratitis in a Danish population from 2000 to 2013. Acta Ophthalmol 2015; 93: 54-58
    CrossrefPubMedGoogle Scholar
  • 14 Kaufman HE, Wood RM. Mycotic Keratitis. Am J Ophthalmol 1965; 59: 993-1000
    CrossrefPubMedGoogle Scholar
  • 15 Thomas PA. Fungal infections of the cornea. Eye (Lond) 2003; 17: 852-862
    CrossrefPubMedGoogle Scholar
  • 16 Naumann GOH. Pathologie des Auges I. Berlin: Springer; 1997: 507-692
    CrossrefGoogle Scholar
  • 17 Thomas PA, Leck AK, Myatt M. Characteristic clinical features as an aid to the diagnosis of suppurative keratitis caused by filamentous fungi. Br J Ophthalmol 2005; 89: 1554-1558
    CrossrefPubMedGoogle Scholar
  • 18 Yanoff M, Duker JS, Augsburger JJ. Ophthalmology. 4th ed. Elsevier Health Sciences; 2014: 217-227
    Google Scholar
  • 19 Badenoch PR, Coster DJ. Antimicrobial activity of topical anaesthetic preparations. Br J Ophthalmol 1982; 66: 364-367
    CrossrefPubMedGoogle Scholar
  • 20 Pleyer U, Behrens-Baumann W. Bakterielle Keratitis – Aktuelle Aspekte zur Diagnostik. Ophthalmologe 2007; 104: 9-14
    CrossrefPubMedGoogle Scholar
  • 21 Rostane H, Saint-Jean C, Batellier L et al. Effects of topical anaesthetics and fluorescein on the real-time PCR used for the diagnosis of Herpesviruses and Acanthamoeba keratitis. Br J Ophthalmol 2006; 90: 1354-1356
    CrossrefPubMedGoogle Scholar
  • 22 Kaye SB, Rao PG, Smith G et al. Simplifying collection of corneal specimens in cases of suspected bacterial keratitis. J Clin Microbiol 2003; 41: 3192-3197
    CrossrefPubMedGoogle Scholar
  • 23 Pakzad-Vaezi K, Levasseur SD, Schendel S et al. The corneal ulcer one-touch study: a simplified microbiological specimen collection method. Am J Ophthalmol 2015; 159: 37-43
    CrossrefPubMedGoogle Scholar
  • 24 McLeod SD, Kumar A, Cevallos V et al. Reliability of transport medium in the laboratory evaluation of corneal ulcers. Am J Ophthalmol 2005; 140: 1027-1031
    CrossrefPubMedGoogle Scholar
  • 25 Kuo IC, Cevallos V, Troyer R et al. Efficacy of transport media use versus direct inoculation of blood agar plates in the microbiologic evaluation of experimental Streptococcus pneumoniae keratitis. Cornea 2003; 22: 249-253
    CrossrefPubMedGoogle Scholar
  • 26 Niki M, Eguchi H, Hayashi Y et al. Ineffectiveness of intrastromal voriconazole for filamentous fungal keratitis. Clin Ophthalmol 2014; 8: 1075-1079
    PubMedGoogle Scholar
  • 27 Brooks JG, Coster DJ. Non-ulcerative fungal keratitis diagnosed by posterior lamellar biopsy. Aust N Z J Ophthalmol 1993; 21: 115-119
    CrossrefPubMedGoogle Scholar
  • 28 Bharathi MJ, Ramakrishnan R, Meenakshi R et al. Microbiological diagnosis of infective keratitis: comparative evaluation of direct microscopy and culture results. Br J Ophthalmol 2006; 90: 1271-1276
    CrossrefPubMedGoogle Scholar
  • 29 Copeland R, Afshari N. Copeland and Afshariʼs Principles and Practice of Cornea. 1st. ed. New Delhi: Jaypee Brothers Medical Publishers; 2012: 195-213
    Google Scholar
  • 30 Alfonso EC. Genotypic identification of Fusarium species from ocular sources: comparison to morphologic classification and antifungal sensitivity testing (an AOS thesis). Trans Am Ophthalmol Soc 2008; 106: 227-239
    PubMedGoogle Scholar
  • 31 Richardson MD, Warnock DW. Fungal Infection. 3rd. ed. Chichester: Blackwell Publishers; 2003: 14-28
    CrossrefGoogle Scholar
  • 32 Das S, Sharma S, Kar S et al. Is inclusion of Sabouraud dextrose agar essential for the laboratory diagnosis of fungal keratitis?. Indian J Ophthalmol 2010; 58: 281-286
    CrossrefPubMedGoogle Scholar
  • 33 Thomas PA, A Teresa P. Theodore J et al. PCR for the molecular diagnosis of mycotic keratitis. Expert Rev Mol Diagn 2012; 12: 703-718
    CrossrefPubMedGoogle Scholar
  • 34 Degorge S, Benallaoua D, Semoun O et al. New strategy for rapid diagnosis and characterization of keratomycosis. Ophthalmology 2012; 119: 945-950
    CrossrefPubMedGoogle Scholar
  • 35 Vengayil S, Panda A, Satpathy G et al. Polymerase chain reaction-guided diagnosis of mycotic keratitis: a prospective evaluation of its efficacy and limitations. Invest Ophthalmol Vis Sci 2009; 50: 152-156
    CrossrefPubMedGoogle Scholar
  • 36 Taravati P, Lam D, Van Gelder RN. Role of molecular diagnostics in ocular microbiology. Curr Ophthalmol Rep 2013; 1: 181-189
    CrossrefPubMedGoogle Scholar
  • 37 Ferrer C, Alio JL. Evaluation of molecular diagnosis in fungal keratitis. Ten years of experience. J Ophthalmic Inflamm Infect 2011; 1: 15-22
    CrossrefPubMedGoogle Scholar
  • 38 Kim E, Chidambaram JD, Srinivasan M et al. Prospective comparison of microbial culture and polymerase chain reaction in the diagnosis of corneal ulcer. Am J Ophthalmol 2008; 146: 714-723.e1
    CrossrefPubMedGoogle Scholar
  • 39 Bader O, Weig M, Taverne-Ghadwal L et al. Improved clinical laboratory identification of human pathogenic yeasts by matrix-assisted laser desorption ionization time-of-flight mass spectrometry. Clin Microbiol Infect 2011; 17: 1359-1365
    CrossrefPubMedGoogle Scholar
  • 40 De Carolis E, Posteraro B, Lass-Flörl C et al. Species identification of Aspergillus, Fusarium and Mucorales with direct surface analysis by matrix-assisted laser desorption ionization time-of-flight mass spectrometry. Clin Microbiol Infect 2012; 18: 475-484
    CrossrefPubMedGoogle Scholar
  • 41 Jung JS, Popp C, Sparbier K et al. Evaluation of matrix-assisted laser desorption ionization-time of flight mass spectrometry for rapid detection of β-lactam resistance in Enterobacteriaceae derived from blood cultures. J Clin Microbiol 2014; 52: 924-930
    CrossrefPubMedGoogle Scholar
  • 42 Vaddavalli PK, Garg P, Sharma S et al. Role of confocal microscopy in the diagnosis of fungal and acanthamoeba keratitis. Ophthalmology 2011; 118: 29-35
    CrossrefPubMedGoogle Scholar
  • 43 Nielsen E, Heegaard S, Prause JU et al. Fungal keratitis – improving diagnostics by confocal microscopy. Case Rep Ophthalmol 2013; 4: 303-310
    CrossrefPubMedGoogle Scholar
  • 44 Soliman W, Fathalla AM, El-Sebaity DM et al. Spectral domain anterior segment optical coherence tomography in microbial keratitis. Graefes Arch Clin Exp Ophthalmol 2013; 251: 549-553
    CrossrefPubMedGoogle Scholar
  • 45 Martone G, Pichierri P, Franceschini R et al. In vivo confocal microscopy and anterior segment optical coherence tomography in a case of alternaria keratitis. Cornea 2011; 30: 449-453
    CrossrefPubMedGoogle Scholar
  • 46 Hau SC, Dart JK, Vesaluoma M et al. Diagnostic accuracy of microbial keratitis with in vivo scanning laser confocal microscopy. Br J Ophthalmol 2010; 94: 982-987
    CrossrefPubMedGoogle Scholar
  • 47 Mølgaard-Nielsen D, Pasternak B, Hviid A. Use of oral fluconazole during pregnancy and the risk of birth defects. N Engl J Med 2013; 369: 830-839
    CrossrefPubMedGoogle Scholar
  • 48 Aust R, Kruse FE, Wildfeuer A et al. Fluconazolspiegel im Kammerwasser nach oraler Wirkstoffgabe beim Menschen. Ophthalmologe 1995; 92: 829-832
    PubMedGoogle Scholar
  • 49 Urbak SF, Degn T. Fluconazole in the treatment of candida albicans endophthalmitis. Acta Ophthalmol 1992; 70: 528-529
    PubMedGoogle Scholar
  • 50 Walsh TJ, Driscoll T, Milligan PA et al. Pharmacokinetics, safety, and tolerability of voriconazole in immunocompromised children. Antimicrob Agents Chemother 2010; 54: 4116-4123
    CrossrefPubMedGoogle Scholar
  • 51 Ally R, Schürmann D, Kreisel W et al. A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients. Clin Infect Dis 2001; 33: 1447-1454
    CrossrefPubMedGoogle Scholar
  • 52 Lazarus HM, Blumer JL, Yanovich S et al. Safety and pharmacokinetics of oral voriconazole in patients at risk of fungal infection: a dose escalation study. J Clin Pharmacol 2002; 42: 395-402
    CrossrefPubMedGoogle Scholar
  • 53 Purkins L, Wood N, Ghahramani P et al. Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens. Antimicrob Agents Chemother 2002; 46: 2546-2553
    CrossrefPubMedGoogle Scholar
  • 54 Vorwerk CK, Tuchen S, Streit F et al. Aqueous humor concentrations of topically administered caspofungin in rabbits. Ophthalmic Res 2009; 41: 102-105
    CrossrefPubMedGoogle Scholar
  • 55 Thiel MA, Zinkernagel AS, Burhenne J et al. Voriconazole concentration in human aqueous humor and plasma during topical or combined topical and systemic administration for fungal keratitis. Antimicrob Agents Chemother 2007; 51: 239-244
    CrossrefPubMedGoogle Scholar
  • 56 Lau D, Leung L, Ferdinands M et al. Penetration of 1 % voriconazole eye drops into human vitreous humour: a prospective, open-label study. Clin Experiment Ophthalmol 2009; 37: 197-200
    CrossrefPubMedGoogle Scholar
  • 57 Prajna NV, Krishnan T, Mascarenhas J et al. The mycotic ulcer treatment trial: a randomized trial comparing natamycin vs. voriconazole. JAMA Ophthalmol 2013; 131: 422-429
    CrossrefPubMedGoogle Scholar
  • 58 Giaconi JA, Marangon FB, Miller D et al. Voriconazole and fungal keratitis: a report of two treatment failures. J Ocul Pharmacol Ther 2006; 22: 437-439
    CrossrefPubMedGoogle Scholar
  • 59 Kalaiselvi G, Narayana S, Krishnan T et al. Intrastromal voriconazole for deep recalcitrant fungal keratitis: a case series. Br J Ophthalmol 2015; 99: 195-198
    CrossrefPubMedGoogle Scholar
  • 60 Prakash G, Sharma N, Goel M et al. Evaluation of intrastromal injection of voriconazole as a therapeutic adjunctive for the management of deep recalcitrant fungal keratitis. Am J Ophthalmol 2008; 146: 56-59
    CrossrefPubMedGoogle Scholar
  • 61 Sharma N, Chacko J, Velpandian T et al. Comparative evaluation of topical versus intrastromal voriconazole as an adjunct to natamycin in recalcitrant fungal keratitis. Ophthalmology 2013; 120: 677-681
    CrossrefPubMedGoogle Scholar
  • 62 Eguchi H, Hayashi Y, Miyamoto T et al. Ineffectiveness of intrastromal voriconazole for filamentous fungal keratitis. Clin Ophthalmol 2014; 1075
    CrossrefPubMedGoogle Scholar
  • 63 Shen YC, Wang CY, Tsai HY, Lee HN. Intracameral voriconazole injection in the treatment of fungal endophthalmitis resulting from keratitis. Am J Ophthalmol 2010; 149: 916-921
    CrossrefPubMedGoogle Scholar
  • 64 Breit SM, Hariprasad SM, Mieler WF et al. Management of endogenous fungal endophthalmitis with voriconazole and caspofungin. Am J Ophthalmol 2005; 139: 135-140
    CrossrefPubMedGoogle Scholar
  • 65 Shen YC, Wang MY, Wang CY et al. Clearance of intravitreal voriconazole. Invest Ophthalmol Vis Sci 2007; 48: 2238-2241
    CrossrefPubMedGoogle Scholar
  • 66 Sabatelli F, Patel R, Mann PA et al. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob Agents Chemother 2006; 50: 2009-2015
    CrossrefPubMedGoogle Scholar
  • 67 Ullmann AJ, Cornely OA, Burchardt A et al. Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection. Antimicrob Agents Chemother 2006; 50: 658-666
    CrossrefPubMedGoogle Scholar
  • 68 Groll AH, Lehrnbecher T. Posaconazole for paediatric patients: status of development and future perspectives. Mycoses 2008; 51 (Suppl. 02) S5-S11
    CrossrefPubMedGoogle Scholar
  • 69 Sponsel WE, Graybill JR, Nevarez HL et al. Ocular and systemic posaconazole (SCH-56592) treatment of invasive Fusarium solani keratitis and endophthalmitis. Br J Ophthalmol 2002; 86: 829-830
    PubMedGoogle Scholar
  • 70 Bullock JD. An outbreak of fusarium keratitis associated with contact lens use in the northeastern United States. Cornea 2008; 27: 973-974
    PubMedGoogle Scholar
  • 71 Störzinger D, Lichtenstern C, Swoboda S et al. Posaconazole in intensive care patients I: invasive fungal infections in surgical intensive care and case presentation. Mycoses 2008; 51 (Suppl. 02) S52-S57
    CrossrefPubMedGoogle Scholar
  • 72 Ullmann AJ, Lipton JH, Vesole DH et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007; 356: 335-347
    CrossrefPubMedGoogle Scholar
  • 73 Walsh TJ, Raad I, Patterson TF et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis 2007; 44: 2-12
    CrossrefPubMedGoogle Scholar
  • 74 Rosa RH, Miller D, Alfonso EC. The changing spectrum of fungal keratitis in south Florida. Ophthalmology 1994; 101: 1005-1013
    CrossrefPubMedGoogle Scholar
  • 75 Behrens-Baumann W, Klinge B. Natamycin (Pimaricin) in der Behandlung der experimentellen Keratomykose. Fortschr Ophthalmol 1990; 87: 237-240
    PubMedGoogle Scholar
  • 76 Lalitha P, Sun CQ, Prajna NV et al. In vitro susceptibility of filamentous fungal isolates from a corneal ulcer clinical trial. Am J Ophthalmol 2014; 157: 318-326
    CrossrefPubMedGoogle Scholar
  • 77 Srinivasan M. Fungal keratitis. Curr Opin Ophthalmol 2004; 15: 321-327
    CrossrefPubMedGoogle Scholar
  • 78 Behrens-Baumann W, Uter W, Ansorg R. Experimentelle Untersuchungen zur lokalen Therapie der Candida-Keratomykose mit Amphotericin B. Klin Monatsbl Augenheilkd 1987; 191: 125-128
    Article in Thieme ConnectPubMedGoogle Scholar
  • 79 Yoon KC, Jeong IY, Im SK et al. Therapeutic effect of intracameral amphotericin B injection in the treatment of fungal keratitis. Cornea 2007; 26: 814-818
    CrossrefPubMedGoogle Scholar
  • 80 Doft BH, Weiskopf J, Nilsson-Ehle I et al. Amphotericin clearance in vitrectomized versus nonvitrectomized eyes. Ophthalmology 1985; 92: 1601-1605
    CrossrefPubMedGoogle Scholar
  • 81 Carrasco MA, Genesoni G. Treatment of severe fungal keratitis with subconjunctival amphotericin B. Cornea 2011; 30: 608-611
    CrossrefPubMedGoogle Scholar
  • 82 Garcia-Valenzuela E, Song CD. Intracorneal injection of amphothericin B for recurrent fungal keratitis and endophthalmitis. Arch Ophthalmol 2005; 123: 1721-1723
    CrossrefPubMedGoogle Scholar
  • 83 Denning DW. Echinocandin antifungal drugs. Lancet 2003; 362: 1142-1151
    CrossrefPubMedGoogle Scholar
  • 84 Durand ML, Kim IK, DʼAmico DJ et al. Successful treatment of Fusarium endophthalmitis with voriconazole and Aspergillus endophthalmitis with voriconazole plus caspofungin. Am J Ophthalmol 2005; 140: 552-554
    CrossrefPubMedGoogle Scholar
  • 85 Neoh CF, Leung L, Misra A et al. Penetration of topically administered 0.5-percent caspofungin eye drops into human aqueous humor. Antimicrob Agents Chemother 2011; 55: 1761-1763
    CrossrefPubMedGoogle Scholar
  • 86 Reboli AC, Rotstein C, Pappas PG et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 2007; 356: 2472-2482
    CrossrefPubMedGoogle Scholar
  • 87 Korting HC, Kiencke P, Nelles S et al. Comparable efficacy and safety of various topical formulations of terbinafine in tinea pedis irrespective of the treatment regimen: results of a meta-analysis. Am J Clin Dermatol 2007; 8: 357-364
    CrossrefPubMedGoogle Scholar
  • 88 Sun XG, Wang ZX, Wang ZQ et al. Pharmacokinetics of terbinafine in the rabbit ocular tissues after topical administration. Ophthalmic Res 2007; 39: 81-83
    CrossrefPubMedGoogle Scholar
  • 89 Liang QF, Jin XY, Wang XL et al. Effect of topical application of terbinafine on fungal keratitis. Chin Med J (Engl) 2009; 122: 1884-1888
    PubMedGoogle Scholar
  • 90 Hofmüller W, Tintelnot K, Seibold M et al. Terbinafin in fungal keratitis. (Noch unveröffentlicht, da der Pilz [vermutlich ein Coelomycet] noch nicht beschrieben wurde und derzeit im RKI Berlin und CBS Utrecht klassifiziert wird).
    PubMedGoogle Scholar
  • 91 Ford JG, Agee S, Greenhaw ST. Successful medical treatment of a case of Paecilomyces lilacinus keratitis. Cornea 2008; 27: 1077-1079
    CrossrefPubMedGoogle Scholar
  • 92 Li L, Wang Z, Li R et al. In vitro evaluation of combination antifungal activity against Fusarium species isolated from ocular tissues of keratomycosis patients. Am J Ophthalmol 2008; 146: 724-728
    CrossrefPubMedGoogle Scholar
  • 93 Larkin DF, Kilvington S, Dart JK. Treatment of Acanthamoeba keratitis with polyhexamethylene biguanide. Ophthalmology 1992; 99: 185-191
    CrossrefPubMedGoogle Scholar
  • 94 Reinhard T, Behrens-Baumann W. Antiinfektiöse medikamentöse Therapie in der Augenheilkunde – Teil 4: Akanthamöben. Klin Monatsbl Augenheilkd 2006; 223: 485-492
    Article in Thieme ConnectPubMedGoogle Scholar
  • 95 Fiscella RG, Moshifar M, Messick CR et al. Polyhexamethylene biguanide (PHMB) in the treatment of experimental Fusarium keratomycosis. Cornea 1997; 16: 447-449
    PubMedGoogle Scholar
  • 96 Behrens-Baumann W, Seibold M, Hofmüller W et al. Benefit of polyhexamethylene biguanide in Fusarium keratitis. Ophthalmic Res 2012; 48: 171-176
    CrossrefPubMedGoogle Scholar
  • 97 Behrens-Baumann W. Ist die fixe Kombination Kortikosteroid/Antibiotikum am Auge indiziert?. Z Prakt Augenheilkd 1995; 16: 361-366
    PubMedGoogle Scholar
  • 98 Newmark E, Ellison AC, Kaufman HE. Combined pimaricin and dexamethasone therapy of keratomycosis. Am J Ophthalmol 1971; 71: 718-722
    CrossrefPubMedGoogle Scholar
  • 99 Francois J, Rijsselaere M. Corticosteroids and ocular mycoses: experimental study. Ann Ophthalmol 1974; 6: 207-217
    PubMedGoogle Scholar
  • 100 Graf K. Über den Einfluss von Kortison auf das Entstehen von Keratomykosen am Kaninchenauge durch saprophytaere Pilze des menschlichen Bindehautsackes. Klin Monatsbl Augenheilkd 1963; 143: 356-362
    PubMedGoogle Scholar
  • 101 Hasany SM, Basu PK, Kazdan JJ. Production of corneal ulcer by opportunistic and saprophytic fungi. 1. The effect of pretreatment of fungi with steroid. Can J Ophthalmol 1973; 8: 119-131
    PubMedGoogle Scholar
  • 102 Hoffmann DH, Schmitz R. Untersuchungen zum Einfluß des Cortisons auf die experimentelle Candidamykose der Kaninchenhornhaut. Graefe Arch Ophthal 1963; 166: 260-276
    PubMedGoogle Scholar
  • 103 Louria DB, Fallon N, Browne HG. The influence of cortisone on experimental fungus infections in mice. J Clin Invest 1960; 39: 1435-1449
    CrossrefPubMedGoogle Scholar
  • 104 OʼDay DM, Moore TE, Aronson SB. Deep fungal corneal abscess. Combined corticosteroid therapy. Arch Ophthalmol 1971; 86: 414-419
    CrossrefPubMedGoogle Scholar
  • 105 Schreiber W, Olbrisch A, Vorwerk CK et al. Combined topical fluconazole and corticosteroid treatment for experimental Candida albicans keratomycosis. Invest Ophthalmol Vis Sci 2003; 44: 2634-2643
    CrossrefPubMedGoogle Scholar
  • 106 Roberts SS. Nystatin in monilia keratoconjunctivitis; a case report. Am J Ophthalmol 1957; 44: 108-109
    CrossrefPubMedGoogle Scholar
  • 107 Perry HD, Doshi SJ, Donnenfeld ED et al. Topical cyclosporin A in the management of therapeutic keratoplasty for mycotic keratitis. Cornea 2002; 21: 161-163
    CrossrefPubMedGoogle Scholar
  • 108 Iseli HP, Thiel MA, Hafezi F et al. Ultraviolet A/riboflavin corneal cross-linking for infectious keratitis associated with corneal melts. Cornea 2008; 27: 590-594
    CrossrefPubMedGoogle Scholar
  • 109 Anwar HM, El-Danasoury AM, Hashem AN. Corneal collagen crosslinking in the treatment of infectious keratitis. Clin Ophthalmol 2011; 5: 1277-1280
    PubMedGoogle Scholar
  • 110 Müller L, Thiel MA, Kipfer-Kauer AI et al. Corneales Crosslinking als zusa¨tzliche Therapieoption bei einschmelzender Hornhaut: eine Fall-Serie. Klin Monatsbl Augenheilkd 2012; 229: 411-415
    Article in Thieme ConnectPubMedGoogle Scholar
  • 111 Price MO, Tenkman LR, Schrier A et al. Photoactivated riboflavin treatment of infectious keratitis using collagen cross-linking technology. J Refract Surg 2012; 28: 706-713
    CrossrefPubMedGoogle Scholar
  • 112 Li Z, Jhanji V, Tao X et al. Riboflavin/ultravoilet light-mediated crosslinking for fungal keratitis. Br J Ophthalmol 2013; 97: 669-671
    CrossrefPubMedGoogle Scholar
  • 113 Shetty R, Nagaraja H, Jayadev C et al. Collagen crosslinking in the management of advanced non-resolving microbial keratitis. Br J Ophthalmol 2014; 98: 1033-1035
    CrossrefPubMedGoogle Scholar
  • 114 Said DG, Elalfy MS, Gatzioufas Z et al. Collagen cross-linking with photoactivated riboflavin (PACK-CXL) for the treatment of advanced infectious keratitis with corneal melting. Ophthalmology 2014; 121: 1377-1382
    CrossrefPubMedGoogle Scholar
  • 115 Ammermann C, Cursiefen C, Hermann M. Antimikrobielles Crosslinking der Hornhaut zur Vermeidung der Keratoplastik à chaud: retrospektive Fallserie. Klin Monatsbl Augenheilkd 2014; 231: 619-625
    Article in Thieme ConnectPubMedGoogle Scholar
  • 116 Martins SAR, Combs JC, Noguera G et al. Antimicrobial efficacy of riboflavin/UVA combination (365 nm) in vitro for bacterial and fungal isolates: a potential new treatment for infectious keratitis. Invest Ophthalmol Vis Sci 2008; 49: 3402-3408
    CrossrefPubMedGoogle Scholar
  • 117 Tayapad JB, Viguilla AQ, Reyes JM. Collagen cross-linking and corneal infections. Curr Opin Ophthalmol 2013; 24: 288-290
    CrossrefPubMedGoogle Scholar
  • 118 Choi KS, Yoon SC, Rim TH et al. Effect of voriconazole and ultraviolet-A combination therapy compared to voriconazole single treatment on Fusarium solani fungal keratitis. J Ocul Pharmacol Ther 2014; 30: 381-386
    CrossrefPubMedGoogle Scholar
  • 119 Arboleda A, Miller D, Cabot F et al. Assessment of rose bengal versus riboflavin photodynamic therapy for inhibition of fungal keratitis isolates. Am J Ophthalmol 2014; 158: 64-70.e2
    CrossrefPubMedGoogle Scholar
  • 120 Behrens-Baumann W. Ergebnisse der Keratoplastik à chaud. Klin Monatsbl Augenheilkd 1984; 185: 25-27
    Article in Thieme ConnectPubMedGoogle Scholar
  • 121 Behrens-Baumann W. Zur klinischen Diagnose der Pilzkeratitis. Z Prakt Augenheilkd 2010; 577-580
    PubMedGoogle Scholar